Biopharma Business

Tag "diabetic nephropathy"

Dutch and German Biotechs enter the Clinic with their First Lanthipeptide

Lanthio Pharma has initiated a Phase I clinical trial with its lanthipeptide candidate MOR107, which is being developed as a therapy for diabetic nephropathy. Lanthio Pharma, a Dutch subsidiary of

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here